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Aim of the study: Positron emission 
tomography–computed tomography 
(PET CT) scan is commonly used in 
current medical oncology practice as 
an imaging method. In this study we 
present data from cancer patients who 
were followed at our clinic and sus-
pected of having tuberculosis during 
PET CT scanning. After the biopsy, they 
were diagnosed with concomitant tu-
berculosis.
Material and methods: In this study, 
14 patients who applied to our clinic 
and followed up due to cancer, and had 
PET CT scanning for the preliminary 
staging or further evaluation, were in-
cluded. The patients were diagnosed 
with metastatic or recurrent disease, 
and their biopsy results revealed tuber-
culosis.
Results: The mean age was 57.8 years 
with SD (standard deviation) 13.1 
years and gender distribution of 78.6% 
(n = 11) females and 21.4% (n = 3) 
males. None of the patients had tu-
berculosis in their personal history 
(0%). Among the patients, 5 (35.7%) 
were diagnosed with tuberculosis 
during the preliminary staging, where-
as 9 (64.3%) were diagnosed during 
the follow-up after the treatment. 
The median time to tuberculosis di-
agnosis was 11 months (min–max: 
3–24 months) after the treatment. 
The most commonly involved lymph 
nodes during PET CT scanning were 
mediastinal in 8 (64.3%), axillary in 
3 (21.4%) and para-aortic in 3 (21.4%) 
patients. The mean SUV
max (maximum 
standardised uptake value) of lymph 
node involved by PET CT scanning was 
defined as 8.5 (SD 2.6).
Conclusions: Despite all improve-
ments in modern medicine, tuberculo-
sis is still a serious public health prob-
lem. It should always be considered in 
differential diagnosis while evaluating 
PET CT scanning results of cancer pa-
tients, because it may cause false pos-
itive results.
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Introduction
One of the most important issues in patients diagnosed with cancer is 
the staging after pathological diagnosis. Appropriate staging at the time of 
diagnosis is one of the most important factors determining the follow up 
and treatment process, and also the prognosis of the disease [1]. Moreover, 
rebiopsy of suspected lesions according to positron emission tomography–
computed tomography (PET CT) scanning to determine the nature of the 
lesion in cancer patients during treatment or follow up periods is the rec-
ommended method for rational patient management. Imaging methods (CT, 
magnetic resonance imaging – MRI) have commonly been used for staging 
and follow up, and PET CT scanning, which has extensively been used in the 
clinical setting in the last decade, aroused high expectations because of its 
high sensitivity and specificity, but later it was realised that this examination 
method should be used more carefully due to its potential for false positivity 
and negativity [2]. False positivity conditions are physiological involvements, 
infections (specific infections), inflammations (soft tissue trauma, collagen 
tissue diseases) and granulomatous infections (sarcoidosis, tuberculosis) 
[3–7]. Although tuberculosis, a chronic problem as old as human history, was 
once a problem mainly for low socioeconomic populations, it has evolved 
into a rising problem in developed countries because of acquired immuno-
suppression conditions (AIDS, haematological and solid organ cancers, med-
ical conditions requiring immunosuppressive treatments). In this present 
study we presented data from cancer patients who were followed at our 
clinic and suspected of having tuberculosis during PET CT scanning. After 
the biopsy, they were diagnosed with concomitant tuberculosis.
Material and methods
A total of 14 patients, who applied to our clinic and were followed up due 
to cancer, and had PET CT scanning for the preliminary staging or further 
evaluation, were included in this present study. The patients were diagnosed 
with metastatic or recurrent disease, and their biopsy results revealed tuber-
culosis. Fine needle aspiration technique was used to perform lymph node 
biopsies from patients suspected of having tuberculosis. Pathological cancer 
diagnoses had already been made in all enrolled patients. Demographic, lab-
oratory, pathological and nuclear imaging results of all patients were record-
ed. Statistical analysis was performed by using the SPSS for Windows 15.0 
(Statistical Package for Social Sciences) package program. Both descriptive 
and analytical statistics were used.
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PET/CT technique
The patients were imaged using a dedicated PET/CT 
system (Discovery-STE 8; General Electric Medical System, 
Milwaukee, WI). The patients fasted for at least 6 hours 
before intravenous administration of 370 to 555 MBq 
(10–15 mCi) 18F-FDG. Pre-injection blood glucose levels 
were measured to ensure that they were below 150 mg/
dl. During the distribution phase, the patients lay supine 
in a quiet room. Combined image acquisition began 55–65 
minutes after FDG injection. First, an unenhanced CT scan 
(5-mm slice thickness) from the vertex of the skull to the 
inferior border of the pelvis was acquired using a stan-
dardised protocol (140 kV and 80 mA). The subsequent 
PET scan was acquired in the 3-dimensional mode (3 min-
utes per bed position) without repositioning the patient 
on the table. Computed tomographic and PET images were 
acquired with the patient breathing shallowly. Attenuation 
was corrected using the CT images.
Results
A total of 14 patients were included in the study. Clini-
cal and demographic characteristics of patients are shown 
in Table 1. The mean age was 57.8 (SD 13.1) years. Of the 
included patients, 11 (78.6%) were females and 3 (21.4%) 
were males. None of the patients had tuberculosis in their 
personal history (0%). When tuberculosis in the family his-
tory was asked about, the history was positive in 3 (21.4%) 
of the patients. The distribution of cancer diagnosis was 
gastric cancer in 3 (21.4%) patients, endometrium cancer 
in 2 (14.3%) patients, rectum cancer in 2 (14.3%) patients, 
cervical cancer in 2 (14.3%) patients and hepatocellular 
carcinoma, hodgkin’s lymphoma and breast, pancreas 
and prostate cancers in 1 patient (for each) (7.1%). Among 
the patients, 5 (35.7%) were diagnosed with tuberculosis 
during the preliminary staging, whereas 9 (64.3%) were di-
agnosed during the follow-up after the treatment. Medias-
tinal lymph nodes were affected lymph nodes in patients 
at preliminary staging. The median time to tuberculosis 
diagnosis was 11 months (min-max: 3–24 months) after 
Table 1. Patient characteristics and demographic features
Parameter Value
Mean age (SD) 57.8 (13.1)
Gender (%) female
male
11 
(78.6%)
3 (21.4%)
Family history of TBC infection 3 (21.4%)
Main diagnosis of 
patients
gastric cancer
endometrium cancer
rectal cancer
cervical cancer
hepatocellular cancer
Hodgkin lymphoma
breast cancer
pancreas cancer
prostate cancer
3 (21.4%)
2 (14.3%)
2 (14.3%)
2 (7.1%)
1 (7.1%)
1 (7.1%)
1 (7.1%)
1 (7.1%)
1 (7.1%)
Tuberculosis 
diagnosis time
initial evaluation
follow-up
5 (35.7%)
9 (64.3%)
Table 2. Laboratory and PET CT findings of patients
Parameter Value
Erythrocyte sedimentation (SD) 41.8 (22.4)
C-reactive protein (SD) 14.4 (5.4)
PET CT SUV max uptake 
value (SD) mediastinal lymph nodes
para-aortic lymph nodes
axillary lymph nodes
8.5 (2.6)
9.5 (2.2)
6.4 (2.3)
6.9 (3.6)
Affected lymph node 
areas in PET CT
mediastinal lymph nodes
para-aortic lymph nodes
axillary lymph nodes
8 (64.3%)
3 (21.4%)
3 (21.4%)
Lymph node size (SD) mediastinal lymph nodes
para-aortic lymph nodes
axillary lymph nodes
25.6 (2.1)
26.3 (1.5)
15 (3.5)
Fig. 1. PET CT images of patients Fig. 2. PET CT images of patients
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the treatment. The most commonly involved lymph nodes 
during PET CT scanning were mediastinal in 8 (64.3%), 
axillary in 3 (21.4%) and para-aortic in 3 (21.4%) patients. 
Mean values for erythrocyte sedimentation, C-reactive 
protein and SUV max at involved lymph nodes detected 
by PET CT scanning were defined as 41.8 (SD 22.4), 14.4 
(SD 5.4) and 8.5 (SD 2.6), in reciprocal order. Laboratory 
and PET CT findings of patients are shown in Table 2. PET 
CT coronal and transverse section images of two patients 
with involvement are shown in Figs. 1–4.
Discussion
Tuberculosis, which may mimic signs of metastatic 
malignancies, should always be considered by clinicians 
during differential diagnosis when evaluating patients 
with cancer. This condition may be encountered either as 
an accompanying tuberculosis infection in a patient with 
a malignancy, or as an infection mimicking recurrence 
signs during the patient follow-up. If it is not detected ear-
ly in both conditions, it may be fatal for the patient. How-
ever, two of our cases (one with cervical cancer and the 
other with gastric cancer) had mediastinal multiple lymph 
nodes with high SUV max values in their follow-up PET CT 
scans performed after the adjuvant treatment. Initially, 
they were considered as recurrence cases, so they received 
chemotherapy. As their clinical performances deteriorated 
during chemotherapy, lymph node biopsy was performed 
and then they were diagnosed with tuberculosis. In such 
conditions, tuberculosis diagnosis is made mainly by mi-
crobiological and histological examinations, because none 
of the available imaging methods is specific for tubercu-
losis [8–10]. Although it is suggested that nodular FDG in-
volvement above 2.5 should lead to malignancy with 80% 
sensitivity and 70% specificity in PET CT examinations, the 
SUV max values of involved lymph nodes were above 2.5 
in all of our patients [4, 9–13]. Moreover, SUV max values 
relating to tuberculosis in PET CT examinations were re-
ported as high in some studies but low in some others, 
published in the literature [14, 15]. Chao-Jung Chen et al. 
diagnosed tuberculosis in a patient who presented with 
high Ca 125 and multiple peritoneal implants resembling 
metastatic ovarian cancer during PET CT scan, and they 
showed that all signs were recovered completely after 
antituberculous treatment [16]. Jin Mo Goo et al. reported 
a 10-case series with pulmonary nodules and positive PET 
CT results. After the biopsy, they diagnosed tuberculosis, 
and they underline that tuberculosis should always be 
considered in endemic regions during PET CT scan eval-
uations [17]. Geng Tian et al. reported 3 patients with ab-
dominal tuberculosis, who had signs similar to peritoneal 
malignancy in PET CT scan, and they concluded that PET 
CT examination was not helpful to resolve the problem 
in such circumstances, so tissue sampling should be per-
formed for the diagnosis [18]. In our series, tuberculosis 
diagnosis was made in 5 patients during the preliminary 
staging and in 9 patients during the follow-up, by biopsy 
results collected from regions suspected for malignancy in 
PET CT examinations. The treatment plan and follow-up 
were completely changed in those patients. If the number 
of patients reported from a single centre were projected 
to the general population of the country, then the size of 
the issue would have been quite significant. In this global 
world, tuberculosis is still a public health problem both for 
developing and developed countries. Therefore, as medical 
oncology specialists, we should definitely consider tuber-
culosis in differential diagnosis of PET CT results
In conclusion, as in most medical conditions, the physi-
cian’s suspicion retains its specific and sensitive value in 
evaluating PET CT results so as not to miss the old enemy, 
tuberculosis, in patients with malignancies, despite all the 
improvements that have been seen in modern medicine.
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